Tarsus Pharmaceuticals, Inc. (TARS) — Financial statements
Income statement, balance sheet, and cash flow for Tarsus Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 451↑146.7% | 183↑948.6% | 17↓32.4% | 26↓54.7% | 57 | |
| Cost of Revenue | 31↑139.2% | 13↑705.1% | 2↑66.8% | 0.96↓54.0% | 2 | |
| Gross Profit | 421↑147.3% | 170↑973.1% | 16↓36.2% | 25↓54.8% | 55 | |
| Operating Expenses | ||||||
| R&D Expenses | 64↑20.5% | 53↑6.1% | 50↑18.0% | 43↑2.2% | 42 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00↓100.0% | 45↑77.0% | 25 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 427↑80.1% | 237↑118.3% | 109↑141.8% | 45↑77.0% | 25 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 492↑69.1% | 291↑82.8% | 159↑81.6% | 88↑30.5% | 67 | |
| Total Costs & Expenses | 522↑72.1% | 304↑89.0% | 161↑81.4% | 89↑28.0% | 69 | |
| Operating Results | ||||||
| Operating Income | -71↑41.1% | -121↑15.8% | -143↓128.3% | -63↓415.9% | -12 | |
| Depreciation & Amortization | 2↑48.2% | 1↑39.7% | 0.88↑169.0% | 0.33↑4.5% | 0.31 | |
| EBITDA | -54↑49.7% | -106↑19.1% | -132↓120.5% | -60↓343.6% | -13 | |
| EBIT | -55↑48.5% | -108↑18.7% | -133↓120.8% | -60↓335.9% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↓10.0% | 8↑6.4% | 7↑395.6% | 1↑3886.1% | 0.04 | |
| Interest Income | 16↑4.9% | 15↑45.2% | 10↑195.4% | 3↑9619.4% | 0.04 | |
| Interest Expense | 9↑20.0% | 7↑130.9% | 3↑56.3% | 2 | 0.00 | |
| Non-Operating Income | -16↓20.8% | -13↓21.2% | -11↓295.8% | -3↓266.0% | 2 | |
| Other Income / Expenses | 7↑31.8% | 5↓31.0% | 7↑1077.5% | 0.62↑138.2% | -2 | |
| Income Before Tax | -64↑44.3% | -116↑15.0% | -136↓118.8% | -62↓350.9% | -14 | |
| Income Tax Expense | 2 | 0.00 | 0.00↑100.0% | -0.00↓107.3% | 0.06 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -66↑42.5% | -116↑15.0% | -136↓118.9% | -62↓349.1% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -66↑42.5% | -116↑15.0% | -136↓118.9% | -62↓349.1% | -14 | |
| Bottom-Line Net Income | -66↑42.5% | -116↑15.0% | -136↓118.9% | -62↓349.1% | -14 | |
| EPS (Basic) | -1.59↑48.2% | -3.07↑33.5% | -4.62↓83.3% | -2.52↓276.1% | -0.67 | |
| EPS (Diluted) | -1.59↑48.2% | -3.07↑33.5% | -4.62↓83.3% | -2.52↓276.1% | -0.67 | |
| Weighted Average Shares | 42↑11.1% | 38↑28.0% | 29↑19.3% | 25↑19.8% | 21 | |
| Weighted Average Diluted Shares | 42↑11.1% | 38↑28.0% | 29↑19.3% | 25↑19.8% | 21 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.